Tseng JS, Hsu KH, Zheng ZR, et al. - Among advanced EGFR (epidermal growth factor receptor)-mutant lung adenocarcinoma patients with EGFR-tyrosine kinase inhibitor (TKI) as first-line therapy, researchers investigated how primary tumor resection (PTR) could impact the results. There were 466 patients included in this study, with 76 (16.3%) receiving PTR. Recurrence was noted in 59 patients following curative surgery, while 17 patients had surgery for diagnostic purposes. A significantly longer progression-free survival and overall survival was observed in PTR patients; they also displayed better performance status, a lower metastatic burden, and much less measurable disease. While comparing PTR patients with the better performance and lower metastatic burden subgroup identified within the non-resection group, survival benefit was still noted. In this study, significantly better results were reported in relation to PTR in advanced lung adenocarcinoma patients managed with EGFR-TKI.